Date: 2013-04-09
Type of information: Grant
Company: Theradiag (France)
Investors: OSEO (France)
Amount: €1.2 million
Funding type: grant
Planned used: CaReNA is a collaborative project between Splicos, alternative RNA splicing specialist and project-lead, Theradiag and the CNRS (French National Center for Research and Science) for the development of RNA-targeting therapeutic and diagnostic solutions in the treatment of HIV/AIDS and obesity. As part of the project, Theradiag will receive €1.2 million for developing and implementing 4 new diagnostic kits. Theradiag will develop 2 new companion diagnostic kits to Splicos’ therapeutics, one for the treatment of HIV /AIDS and another for the monitoring of diabetes and associated metabolic disorders. These tests will be implemented right from the clinical development phases and will enable physicians to optimize patient care (as part of the theranostic strategy). A third test will be developed for early monitoring of HIV infection and disease evolution. A fourth test will allow for the assessment of patient response and/or resistance to antiretroviral treatments through the quantification of predicting miRNAs.
Others: Theradiag, a company specializing in theranostic and in vitro diagnostics, has been granted financial support by Oséo, the French Agency for Innovation, for its participation in CaReNA. Total development costs for the entire project could reach €18 M.
Therapeutic area: Diagnostic - Infectious diseases
